US Bancorp’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,474
| Closed | -$4.48K | – | 4409 |
|
|
2024
Q4 | $4.48K | Sell |
1,474
-471
| -24% | -$2.05K | ﹤0.01% | 3675 |
|
|
2024
Q3 | $10.1K | Buy |
1,945
+175
| +10% | +$870 | ﹤0.01% | 3363 |
|
|
2024
Q2 | $4.55K | Sell |
1,770
-1,232
| -41% | -$4.21K | ﹤0.01% | 3549 |
|
|
2024
Q1 | $14.8K | Buy |
3,002
+573
| +24% | +$3.39K | ﹤0.01% | 3205 |
|
|
2023
Q4 | $21.4K | Sell |
2,429
-846
| -26% | -$6.93K | ﹤0.01% | 3021 |
|
|
2023
Q3 | $37.6K | Buy |
3,275
+60
| +2% | +$1.15K | ﹤0.01% | 2581 |
|
|
2023
Q2 | $81.4K | Sell |
3,215
-763
| -19% | -$23.8K | ﹤0.01% | 2290 |
|
|
2023
Q1 | $128K | Sell |
3,978
-22,403
| -85% | -$698K | ﹤0.01% | 2074 |
|
|
2022
Q4 | $487K | Buy |
26,381
+9,382
| +55% | +$215K | ﹤0.01% | 1412 |
|
|
2022
Q3 | $458K | Buy |
16,999
+16,147
| +1,895% | +$328K | ﹤0.01% | 1431 |
|
|
2022
Q2 | $12K | Sell |
852
-1,254
| -60% | -$19.3K | ﹤0.01% | 3321 |
|
|
2022
Q1 | $41K | Sell |
2,106
-425
| -17% | -$6.45K | ﹤0.01% | 2726 |
|
|
2021
Q4 | $41K | Buy |
2,531
+2,256
| +820% | +$37.6K | ﹤0.01% | 2756 |
|
|
2021
Q3 | $8K | Hold |
275
| – | – | ﹤0.01% | 3535 |
|
|
2021
Q2 | $8K | Hold |
275
| – | – | ﹤0.01% | 3501 |
|
|
2021
Q1 | $8K | Buy |
275
+18
| +7% | +$498 | ﹤0.01% | 3383 |
|
|
2020
Q4 | $7K | Hold |
257
| – | – | ﹤0.01% | 3321 |
|
|
2020
Q3 | $6K | Hold |
257
| – | – | ﹤0.01% | 3260 |
|
|
2020
Q2 | $6K | Buy |
257
+59
| +30% | +$1.17K | ﹤0.01% | 3275 |
|
|
2020
Q1 | $3K | Hold |
198
| – | – | ﹤0.01% | 3408 |
|
|
2019
Q4 | $3K | Sell |
198
-545
| -73% | -$8.45K | ﹤0.01% | 3427 |
|
|
2019
Q3 | $10K | Buy |
743
+198
| +36% | +$2.42K | ﹤0.01% | 3061 |
|
|
2019
Q2 | $7K | Sell |
545
-128
| -19% | -$1.61K | ﹤0.01% | 3212 |
|
|
2019
Q1 | $11K | Buy |
673
+173
| +35% | +$3K | ﹤0.01% | 3041 |
|
|
2018
Q4 | $10K | Sell |
500
-260
| -34% | -$5.73K | ﹤0.01% | 3043 |
|
|
2018
Q3 | $19K | Hold |
760
| – | – | ﹤0.01% | 2946 |
|
|
2018
Q2 | $21K | Buy |
760
+260
| +52% | +$7.81K | ﹤0.01% | 2924 |
|
|
2018
Q1 | $15K | Buy |
+500
| New | +$16.1K | ﹤0.01% | 3042 |
|
Other funds holding RVNC
US Bancorp's RVNC Position: Q1 2025 in Review
US Bancorp sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 1,474 shares — an estimated $4.48K sold.
US Bancorp first reported a position in RVNC in Q1 2018 and held it in 28 quarters. The position peaked at $487K in Q4 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- US Bancorp reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- US Bancorp sold 1,474 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $4.48K.
- US Bancorp first reported a position in Revance Therapeutics, Inc. in Q1 2018 and held it in 28 quarters.
- US Bancorp's Revance Therapeutics, Inc. position peaked at $487K in Q4 2022.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on US Bancorp's 13F filing for Q1 2025, filed 8 May 2025.